Journal article icon

Journal article

Trimethoprim-sulfamethoxazole versus trimethoprimsulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): A multicentre, double-blind, non-inferiority, randomised controlled trial

Abstract:

Background Melioidosis, an infectious disease caused by the Gram-negative bacillus Burkholderia pseudomallei, is difficult to cure. Antimicrobial treatment comprises intravenous drugs for at least 10 days, followed by oral drugs for at least 12 weeks. The standard oral regimen based on trial evidence is trimethoprim-sulfamethoxaxole (TMP-SMX) plus doxycycline. This regimen is used in Thailand but is associated with side-effects and poor adherence by patients, and TMP-SMX alone is recommended ...

Expand abstract

Actions


Access Document


Authors


Chetchotisakd, P More by this author
Anunnatsiri, S More by this author
Mootsikapun, P More by this author
Wongrattanacheewin, S More by this author
Chierakul, W More by this author
Expand authors...
Journal:
The Lancet
Volume:
383
Issue:
9919
Pages:
807-814
Publication date:
2014
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
URN:
uuid:47c7242f-919d-47d0-aa99-83658f3bf350
Source identifiers:
459618
Local pid:
pubs:459618

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP